{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T02:19:20Z","timestamp":1762481960069,"version":"build-2065373602"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T00:00:00Z","timestamp":1751155200000},"content-version":"vor","delay-in-days":179,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine Case Reports"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.rmcr.2025.102249","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T15:47:10Z","timestamp":1751384830000},"page":"102249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Effectiveness of afatinib after long-term gefitinib treatment for EGFR L858R and S768I compound mutation-positive lung adenocarcinoma: A case report"],"prefix":"10.1016","volume":"57","author":[{"given":"Ayuka","family":"Dai-Shinozaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4333-8100","authenticated-orcid":false,"given":"Jun","family":"Sakakibara-Konishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanako C.","family":"Hatanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kento","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naofumi","family":"Shinagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Matsuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Hatanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Konno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmcr.2025.102249_bib1","first-page":"2892","article-title":"EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)","volume":"5","author":"Midha","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.rmcr.2025.102249_bib2","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1111\/j.1349-7006.2007.00607.x","article-title":"Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer","volume":"98","author":"Mitsudomi","year":"2007","journal-title":"Cancer Sci."},{"key":"10.1016\/j.rmcr.2025.102249_bib3","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"Molecular epidemiology study of EGFR mutations in Asian patients with advanced Non\u2013small-cell lung cancer of adenocarcinoma histology (PIONEER)","volume":"9","author":"Shi","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.rmcr.2025.102249_bib4","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.rmcr.2025.102249_bib5","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/annonc\/mdt418","article-title":"Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network","volume":"25","author":"Beau-Faller","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.rmcr.2025.102249_bib6","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.rmcr.2025.102249_bib7","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin\u2013paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmcr.2025.102249_bib8","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/annonc\/mdv270","article-title":"First-line erlotinib versus gemcitabine\/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study","volume":"26","author":"Wu","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.rmcr.2025.102249_bib9","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1007\/s12253-018-0460-2","article-title":"Large-Scale EGFR mutation testing in clinical practice: analysis of a series of 18,920 non-small cell lung cancer cases","volume":"25","author":"Evans","year":"2019","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.rmcr.2025.102249_bib10","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1158\/1078-0432.CCR-10-3408","article-title":"Effectiveness of tyrosine kinase inhibitors on \u201cUncommon\u201d epidermal growth factor receptor mutations of unknown clinical significance in non\u2013small cell lung cancer","volume":"17","author":"Wu","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.rmcr.2025.102249_bib11","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/01.JTO.0000268677.87496.4c","article-title":"Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China","volume":"2","author":"Wu","year":"2007","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.rmcr.2025.102249_bib12","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1007\/s12253-018-0460-2","article-title":"Large-scale EGFR mutation testing in clinical practice: analysis of a series of 18,920 non-small cell lung cancer cases","volume":"25","author":"Evans","year":"2019","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.rmcr.2025.102249_bib13","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1007\/s10147-013-0602-1","article-title":"Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer","volume":"19","author":"Keam","year":"2014","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.rmcr.2025.102249_bib14","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial","volume":"15","author":"Wu","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.rmcr.2025.102249_bib15","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for Non\u2013small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmcr.2025.102249_bib16","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.rmcr.2025.102249_bib17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(14)71173-8","article-title":"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.rmcr.2025.102249_bib18","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1470-2045(15)00026-1","article-title":"Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.rmcr.2025.102249_bib19","doi-asserted-by":"crossref","first-page":"S1310","DOI":"10.1016\/j.annonc.2023.10.067","article-title":"LBA66 Afatinib versus chemotherapy for treatment-na\u00efve non-small cell lung cancer with a sensitizing uncommon epidermal growth factor receptor mutation: a phase III study (ACHILLES\/TORG1834)","volume":"34","author":"Miura","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.rmcr.2025.102249_bib20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jamaoncol.2023.5013","article-title":"First-Line osimertinib for previously untreated patients with NSCLC and uncommon EGFR mutations","volume":"10","author":"Okuma","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.rmcr.2025.102249_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","volume":"3","author":"Sequist","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.rmcr.2025.102249_bib22","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of Non\u2013small-cell lung cancer to gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmcr.2025.102249_bib23","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med."},{"key":"10.1016\/j.rmcr.2025.102249_bib24","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/pin.13170","article-title":"The Japanese society of pathology practical guidelines on the handling of pathological tissue samples for cancer genomic medicine","volume":"71","author":"Hatanaka","year":"2021","journal-title":"Pathol. Int."},{"key":"10.1016\/j.rmcr.2025.102249_bib25","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1158\/1535-7163.MCT-12-0620","article-title":"EGFR Exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics","volume":"12","author":"Arcila","year":"2013","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.rmcr.2025.102249_bib26","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.lungcan.2017.04.016","article-title":"Uncommon EGFR mutations in advanced non-small cell lung cancer","volume":"109","author":"O'Kane","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.rmcr.2025.102249_bib27","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/sj.onc.1209159","article-title":"Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants","volume":"25","author":"Chen","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.rmcr.2025.102249_bib28","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1158\/1078-0432.CCR-08-1757","article-title":"Functional analysis of Epidermal Growth Factor Receptor (EGFR) mutations and potential implications for EGFR targeted therapy","volume":"15","author":"Kancha","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.rmcr.2025.102249_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2023.116385","article-title":"Six first-line tyrosine kinase inhibitors reveal novel inhibition potential for the EGFR S768I mutation","volume":"461","author":"Wang","year":"2023","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.rmcr.2025.102249_bib30","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.lungcan.2013.01.018","article-title":"Uncommon epidermal growth factor receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance","volume":"80","author":"Massarelli","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.rmcr.2025.102249_bib31","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1158\/1078-0432.CCR-07-5123","article-title":"Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response","volume":"14","author":"Wu","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.rmcr.2025.102249_bib32","doi-asserted-by":"crossref","first-page":"7232","DOI":"10.1158\/1078-0432.CCR-06-0658","article-title":"Update on epidermal growth factor receptor mutations in non\u2013small cell lung cancer","volume":"12","author":"Riely","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.rmcr.2025.102249_bib33","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1158\/1078-0432.CCR-06-0462","article-title":"Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non\u2013small cell lung cancer patients treated with gefitinib or erlotinib","volume":"12","author":"Jackman","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.rmcr.2025.102249_bib34","doi-asserted-by":"crossref","first-page":"13306","DOI":"10.1073\/pnas.0405220101","article-title":"EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib","volume":"101","author":"Pao","year":"2004","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.rmcr.2025.102249_bib35","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1158\/1078-0432.CCR-14-1814","article-title":"A phase Ib dose-escalation study of the oral Pan-PI3K inhibitor Buparlisib (BKM120) in combination with the oral MEK1\/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors","volume":"21","author":"Bedard","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.rmcr.2025.102249_bib36","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1158\/0008-5472.CAN-08-4055","article-title":"PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR","volume":"69","author":"Sos","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.rmcr.2025.102249_bib37","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/2159-8290.CD-12-0108","article-title":"HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR -Mutant lung cancers that lack the second-site EGFR T790M mutation","volume":"2","author":"Takezawa","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.rmcr.2025.102249_bib38","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"1979","journal-title":"Science"},{"key":"10.1016\/j.rmcr.2025.102249_bib39","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1200\/JCO.18.01585","article-title":"EGFR -Mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes","volume":"37","author":"Marcoux","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.rmcr.2025.102249_bib40","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.jtho.2019.06.002","article-title":"Concurrent RB1 and TP53 alterations define a subset of EGFR-Mutant lung cancers at risk for histologic transformation and inferior clinical outcomes","volume":"14","author":"Offin","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.rmcr.2025.102249_bib41","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.lungcan.2019.11.018","article-title":"Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC","volume":"139","author":"Yang","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.rmcr.2025.102249_bib42","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1111\/cas.15769","article-title":"Real\u2010world clinical analysis in 190 advanced NSCLC patients with uncommon EGFR mutations: a multi\u2010center study","volume":"114","author":"Qin","year":"2023","journal-title":"Cancer Sci."},{"key":"10.1016\/j.rmcr.2025.102249_bib43","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/cam4.2652","article-title":"Real\u2010world efficacy and potential mechanism of resistance of icotinib in Asian advanced non\u2010small cell lung cancer with EGFR uncommon mutations: a multi\u2010center study","volume":"9","author":"Lei","year":"2020","journal-title":"Cancer Med."},{"key":"10.1016\/j.rmcr.2025.102249_bib44","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.lungcan.2020.09.024","article-title":"Impact of HER2 expression on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: a HER2-CS study subset analysis","volume":"150","author":"Ohashi","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.rmcr.2025.102249_bib45","doi-asserted-by":"crossref","first-page":"13237","DOI":"10.1073\/pnas.1200105109","article-title":"Functional isolation of activated and unilaterally phosphorylated heterodimers of ERBB2 and ERBB3 as scaffolds in ligand-dependent signaling","volume":"109","author":"Zhang","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.rmcr.2025.102249_bib46","doi-asserted-by":"crossref","first-page":"21608","DOI":"10.1073\/pnas.0912101106","article-title":"Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3","volume":"106","author":"Jura","year":"2009","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.rmcr.2025.102249_bib47","doi-asserted-by":"crossref","first-page":"7406","DOI":"10.1038\/s41598-019-43678-6","article-title":"EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients","volume":"9","author":"Scharpenseel","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.rmcr.2025.102249_bib48","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.rmcr.2025.102249_bib49","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1590\/1414-431X20144099","article-title":"Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data","volume":"47","author":"Jorge","year":"2014","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.rmcr.2025.102249_bib50","doi-asserted-by":"crossref","first-page":"5891","DOI":"10.1158\/0008-5472.CAN-14-0184","article-title":"\u03b2-Catenin contributes to lung tumor development induced by EGFR mutations","volume":"74","author":"Nakayama","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.rmcr.2025.102249_bib51","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/nm.3388","article-title":"The quest to overcome resistance to EGFR-targeted therapies in cancer","volume":"19","author":"Chong","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.rmcr.2025.102249_bib52","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12885-016-2201-9","volume":"16","author":"Lee","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.rmcr.2025.102249_bib53","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1038\/onc.2008.109","article-title":"BIBW2992, an irreversible EGFR\/HER2 inhibitor highly effective in preclinical lung cancer models","volume":"27","author":"Li","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.rmcr.2025.102249_bib54","doi-asserted-by":"crossref","first-page":"33602","DOI":"10.18632\/oncotarget.5286","article-title":"The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer","volume":"6","author":"Yonesaka","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.rmcr.2025.102249_bib55","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1158\/2159-8290.CD-21-0715","article-title":"Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor\u2013resistant, EGFR -Mutated non\u2013small cell lung cancer","volume":"12","author":"J\u00e4nne","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.rmcr.2025.102249_bib56","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1200\/JCO.23.01476","article-title":"HERTHENA-Lung01, a phase II trial of Patritumab Deruxtecan (HER3-DXd) in epidermal growth factor receptor\u2013mutated Non\u2013small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy","volume":"41","author":"Yu","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.rmcr.2025.102249_bib57","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2217\/fon-2023-0602","article-title":"HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR -mutated NSCLC after a third-generation EGFR TKI","volume":"20","author":"Mok","year":"2024","journal-title":"Future Oncol."}],"container-title":["Respiratory Medicine Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213007125000851?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213007125000851?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T02:14:42Z","timestamp":1762481682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213007125000851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":57,"alternative-id":["S2213007125000851"],"URL":"https:\/\/doi.org\/10.1016\/j.rmcr.2025.102249","relation":{},"ISSN":["2213-0071"],"issn-type":[{"type":"print","value":"2213-0071"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of afatinib after long-term gefitinib treatment for EGFR L858R and S768I compound mutation-positive lung adenocarcinoma: A case report","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmcr.2025.102249","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102249"}}